Zomedica Corp (AMEX:ZOM) has a beta value of 1.04 and has seen 1.35 million shares traded in the recent trading session. The ZOM stock price is -76.92% off its 52-week high price of $0.23 and 7.69% above the 52-week low of $0.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.68 million shares traded. The 3-month trading volume is 3.05 million shares.
The consensus among analysts is that Zomedica Corp (ZOM) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zomedica Corp (AMEX:ZOM) trade information
Sporting 0.08% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ZOM stock price touched $0.13 or saw a rise of 0.69%. Year-to-date, Zomedica Corp shares have moved -36.51%, while the 5-day performance has seen it change -2.90%. Over the past 30 days, the shares of Zomedica Corp (AMEX:ZOM) have changed -2.23%. Short interest in the company has seen 46.06 million shares shorted with days to cover at 15.52.
Zomedica Corp (ZOM) estimates and forecasts
The company’s shares have lost -2.53% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 35.40%.
1 analysts offering their estimates for the company have set an average revenue estimate of 6.26M for the current quarter. 1 have an estimated revenue figure of 6.13M for the next ending quarter. Year-ago sales stood 5.48M and 6.02M respectively for this quarter and the next, and analysts expect sales will grow by 14.20% for the current quarter and 35.40% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 27.70% over the past 5 years.
ZOM Dividends
Zomedica Corp is expected to release its next earnings report on 2024-May-09 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Zomedica Corp (AMEX:ZOM)’s Major holders
Insiders own 1.78% of the company shares, while shares held by institutions stand at 8.62% with a share float percentage of 8.78%. Investors are also buoyed by the number of investors in a company, with Zomedica Corp having a total of 101.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 29.93 million shares worth more than $382.18 million. As of 2024-06-30, VANGUARD GROUP INC held 3.054% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 26.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $334.65 million and represent 2.6742% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 30, 2024, the former fund manager holds about 3.38% shares in the company for having 33.16 shares of worth $4.15 million while later fund manager owns 13.41 shares of worth $1.68 million as of Jun 30, 2024, which makes it owner of about 1.37% of company’s outstanding stock.
